Women's Cancer Program

妇女癌症研究项目摘要 妇女癌症计划（WCP）是一个高度互动的，多学科的研究计划共同领导的博士。 Goetz、Degnim和Bakkum-Gamez由61名基础和人口科学家以及临床科学家组成 来自明尼苏达州罗切斯特、亚利桑那州和佛罗里达的马约诊所的14个部门和中心的研究人员。其 总体目标是促进对乳腺和妇科疾病的理解和管理策略， 癌的大量的计划内互动反映了多学科的WCP团队，重点是4 主要具体目标：1）基因组学：确定宿主和肿瘤的遗传改变; 2）生物学：定义 女性癌症生物学中的关键介质和途径; 3）风险评估的进展：定义 风险增加的妇女亚组;和4）新的临床策略：开发和测试创新的临床 战略，特别是基于具体目标1-3的发现。WCP坚实的科学基础和 相互作用的机会导致了马约诊所乳腺和卵巢孢子的更新， 新的站起来癌症，国防部，和多个R 01赠款在当前项目期间。所有这些赠款 在马约诊所和包括联盟在内的临床试验网络内支持制药商发起的临床试验 临床试验，转化乳腺癌研究联盟，和站起来癌症 合作，项目成员广泛参与。2010年内直接同行审议赠款供资总额 该计划为530万美元，其中56%来自NCI。该计划还有1440万美元的直接，非同行评审 经费自2013年以来，该计划的成员已经为文献贡献了978篇出版物; 49%的人代表了 计划内工作，29%反映了计划间合作，158（16%）在期刊上， 影响因子≥10。其中一些工作已经改变了临床实践，包括对BRCA 2变体的重新分类 重要性未知;制定和实施新的乳腺癌风险模型;共同制定 Rucaparib的使用，导致FDA批准PARP抑制剂并将其扩展到高级别浆液性卵巢癌 具有生殖系BRCA 1或BRCA 2突变的癌症;以及临床药物遗传学的发展 实施联盟（CPIC）关于使用CYP 2D 6基因型指导的实践指南 他莫昔芬治疗。WCP成员受益于众多共享资源的使用，特别是 生物标本采集和处理，病理学研究，生物统计学，调查研究，以及 MCCC临床研究办公室。为了促进新的合作并保持正在进行的合作，该计划 每月科学研讨会和乳腺癌和妇科癌症疾病小组会议，每周 乳腺癌和妇科癌症研究人员的多学科会议， 妇科癌症会议，以及每年的多学科乳腺CME课程，在3个 马约研究中心。妇女癌症相关研究得到了机构和癌症中心的大力支持， 教育、外展和临床实践的努力。

WOMEN'S CANCER PROGRAM PROJECT SUMMARY The Women's Cancer Program (WCP) is a highly interactive, multidisciplinary research program co-led by Drs. Goetz, Degnim, and Bakkum-Gamez and composed of 61 basic and population scientists and clinical investigators from 14 departments and centers at Mayo Clinic in Rochester, MN; Arizona; and Florida. Its overarching goal is to advance the understanding of, and management strategies for, breast and gynecologic cancers. The substantial intraprogrammatic interactions reflect multidisciplinary WCP teams that focus on 4 major Specific Aims: 1) Genomics: to determine both host and tumor genetic alterations; 2) Biology: to define key mediators and pathways in the biology of women's cancers; 3) Advances in risk assessment: to define subgroups of women at increased risk; and 4) New clinical strategies: to develop and test innovative clinical strategies, especially based on discoveries from Specific Aims 1-3. The WCP's solid scientific base and opportunities for interactions have resulted in the renewal of the Mayo Clinic Breast and Ovarian SPOREs and new Stand Up to Cancer, DoD, and multiple R01 grants during the current project period. All of these grants support investigator-initiated clinical trials at Mayo Clinic and within clinical trial networks, including the Alliance for Clinical Trials, the Translational Breast Cancer Research Consortium, and the Stand Up to Cancer collaboration, with broad participation by Program members. Total direct peer-reviewed grant funding within the Program is $5.3M, with 56% from NCI. The Program has an additional $14.4M in direct, non-peer-reviewed funding. Since 2013, Program members have contributed 978 publications to the literature; 49% represent intraprogrammatic work, 29% reflect interprogrammatic collaborations, and 158 (16%) are in journals with an impact factor ≥10. Some of this work has changed clinical practice, including reclassification of BRCA2 variants of unknown significance; development and implementation of a new breast cancer risk model; co-development of rucaparib, resulting in FDA approval and extension of PARP inhibitors beyond high-grade serous ovarian cancers with germline BRCA1 or BRCA2 mutations; and the development of Clinical Pharmacogenetics Implementation Consortium (CPIC) practice guidelines regarding the use of CYP2D6 genotype to guide tamoxifen treatment. WCP members benefit from the use of numerous Shared Resources, especially Biospecimens Accessioning and Processing, Pathology Research, Biostatistics, Survey Research, and the MCCC Clinical Research Office. To catalyze new and maintain ongoing collaborations, the Program has monthly scientific symposia and Breast and Gynecologic Cancer Disease Group meetings, weekly multidisciplinary conferences for breast and gynecologic cancer researchers, quarterly combined breast and gynecologic cancer conferences, and yearly multidisciplinary breast CME courses that rotate among the 3 Mayo sites. There is significant institutional and Cancer Center support for women's cancer–related research, education, outreach, and clinical practice endeavors.